Mounjaro shows promise in treating obesity and diabetes

Mounjaro is a new weight-loss drug made by Eli Lilly. It works by mimicking two hormones in the body: GLP-1 and GIP. These hormones help manage blood sugar levels and control appetite. In comparison, Ozempic, another popular weight-loss and diabetes medication, only targets the GLP-1 hormone. Mounjaro has quickly become popular in India. This is important because the country is facing problems with obesity and diabetes. The drug is available for about Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial. A patient may spend up to Rs 17,500 each month, depending on their prescription. Mounjaro is approved for treating Type 2 diabetes and is given as a weekly injection. It helps reduce blood sugar levels by increasing insulin release when needed and slowing sugar release from the liver. It also promotes feelings of fullness and can help decrease appetite and food intake. However, it can cause side effects like nausea, vomiting, and diarrhea. Although both Mounjaro and Ozempic lower blood sugar in Type 2 diabetes, they are different. Mounjaro's unique action on both GLP-1 and GIP receptors can lead to more weight loss. Studies show it can lead to weight losses of up to 20 kg over 72 weeks, making it a highly effective treatment. Mounjaro is suitable for adults with Type 2 diabetes who need better blood sugar control and for those who are obese or overweight. However, it is not recommended for pregnant women, children, or individuals with certain medical histories. India is experiencing a surge in obesity and diabetes rates. The World Health Organization states that a BMI over 25 is considered overweight, while a BMI over 30 is obese. By 2045, diabetes cases in India are estimated to rise significantly. Experts suggest new guidelines are needed to effectively address obesity in the country. Current research indicates that BMI alone does not adequately measure obesity in Indians. A new classification system identifies two stages of obesity based on health impacts. The aim is to provide better care and prevention strategies for those affected.